Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.1800
- TODAY'S CHANGE (%)-0.1800 (-3.3582%)
- Bid / Lots5.1800/ 1
- Ask / Lots5.3000/ 2
- Open / Previous Close5.3400 / 5.3600
- Day Range
- 52 Week Range
- Volume328,775
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 1630 | 5.33 |
| 09:33 ET | 3466 | 5.39 |
| 09:37 ET | 250 | 5.3355 |
| 09:39 ET | 3438 | 5.2 |
| 09:42 ET | 1090 | 5.1857 |
| 09:44 ET | 5101 | 5.14 |
| 09:46 ET | 215 | 5.1216 |
| 09:48 ET | 4268 | 5.15 |
| 09:50 ET | 4944 | 5.14 |
| 09:51 ET | 15401 | 5.1 |
| 09:53 ET | 1295 | 5.13 |
| 09:57 ET | 455 | 5.145 |
| 10:02 ET | 419 | 5.11 |
| 10:04 ET | 1292 | 5.125 |
| 10:06 ET | 8180 | 5.095 |
| 10:08 ET | 1100 | 5.1 |
| 10:09 ET | 5989 | 5.1187 |
| 10:11 ET | 500 | 5.1 |
| 10:15 ET | 622 | 5.12 |
| 10:18 ET | 200 | 5.14 |
| 10:20 ET | 524 | 5.165 |
| 10:22 ET | 400 | 5.16 |
| 10:24 ET | 1294 | 5.1522 |
| 10:27 ET | 2237 | 5.1516 |
| 10:29 ET | 1636 | 5.17 |
| 10:31 ET | 1100 | 5.17 |
| 10:33 ET | 606 | 5.18 |
| 10:38 ET | 100 | 5.19 |
| 10:40 ET | 200 | 5.21 |
| 10:42 ET | 1700 | 5.2292 |
| 10:45 ET | 1395 | 5.245 |
| 10:47 ET | 200 | 5.2331 |
| 10:49 ET | 942 | 5.25 |
| 10:51 ET | 3950 | 5.26 |
| 10:54 ET | 700 | 5.2607 |
| 10:56 ET | 200 | 5.25 |
| 10:58 ET | 2699 | 5.2199 |
| 11:00 ET | 100 | 5.21 |
| 11:03 ET | 1150 | 5.21 |
| 11:05 ET | 100 | 5.22 |
| 11:14 ET | 300 | 5.22 |
| 11:18 ET | 100 | 5.21 |
| 11:20 ET | 100 | 5.21 |
| 11:21 ET | 1600 | 5.21 |
| 11:23 ET | 100 | 5.21 |
| 11:25 ET | 100 | 5.21 |
| 11:27 ET | 200 | 5.22 |
| 11:30 ET | 400 | 5.2204 |
| 11:32 ET | 276 | 5.21 |
| 11:36 ET | 100 | 5.23 |
| 11:39 ET | 237 | 5.2284 |
| 11:41 ET | 200 | 5.21 |
| 11:43 ET | 2400 | 5.18 |
| 11:45 ET | 557 | 5.16 |
| 11:48 ET | 100 | 5.16 |
| 11:50 ET | 504 | 5.16 |
| 11:52 ET | 228 | 5.14 |
| 11:56 ET | 2306 | 5.12 |
| 11:57 ET | 131 | 5.12 |
| 12:01 ET | 100 | 5.13 |
| 12:03 ET | 500 | 5.125 |
| 12:06 ET | 7399 | 5.12 |
| 12:08 ET | 1800 | 5.1301 |
| 12:10 ET | 9807 | 5.14 |
| 12:12 ET | 200 | 5.1599 |
| 12:15 ET | 2479 | 5.18 |
| 12:17 ET | 228 | 5.165 |
| 12:19 ET | 200 | 5.162 |
| 12:24 ET | 1500 | 5.18 |
| 12:26 ET | 2320 | 5.22 |
| 12:30 ET | 1579 | 5.23 |
| 12:32 ET | 700 | 5.2597 |
| 12:33 ET | 2454 | 5.2609 |
| 12:35 ET | 529 | 5.25 |
| 12:37 ET | 450 | 5.26 |
| 12:42 ET | 4000 | 5.28 |
| 12:44 ET | 500 | 5.28 |
| 12:46 ET | 200 | 5.29 |
| 12:48 ET | 100 | 5.2999 |
| 12:51 ET | 100 | 5.28 |
| 12:53 ET | 110 | 5.29 |
| 12:55 ET | 4745 | 5.27 |
| 01:00 ET | 219 | 5.275 |
| 01:02 ET | 340 | 5.2725 |
| 01:04 ET | 100 | 5.27 |
| 01:06 ET | 189 | 5.2644 |
| 01:08 ET | 100 | 5.26 |
| 01:09 ET | 100 | 5.25 |
| 01:11 ET | 4079 | 5.24 |
| 01:13 ET | 100 | 5.25 |
| 01:18 ET | 200 | 5.25 |
| 01:22 ET | 300 | 5.2472 |
| 01:26 ET | 100 | 5.26 |
| 01:29 ET | 400 | 5.25 |
| 01:36 ET | 300 | 5.24 |
| 01:44 ET | 4939 | 5.24 |
| 01:45 ET | 10230 | 5.24 |
| 01:47 ET | 200 | 5.25 |
| 01:54 ET | 200 | 5.26 |
| 01:56 ET | 200 | 5.26 |
| 01:58 ET | 200 | 5.26 |
| 02:00 ET | 610 | 5.26 |
| 02:03 ET | 4710 | 5.26 |
| 02:05 ET | 300 | 5.26 |
| 02:07 ET | 100 | 5.26 |
| 02:12 ET | 487 | 5.26 |
| 02:16 ET | 431 | 5.26 |
| 02:20 ET | 100 | 5.26 |
| 02:21 ET | 445 | 5.26 |
| 02:23 ET | 540 | 5.26 |
| 02:27 ET | 200 | 5.28 |
| 02:30 ET | 300 | 5.27 |
| 02:32 ET | 400 | 5.27 |
| 02:38 ET | 810 | 5.26 |
| 02:41 ET | 6424 | 5.2 |
| 02:43 ET | 200 | 5.19 |
| 02:45 ET | 376 | 5.2 |
| 02:48 ET | 575 | 5.204 |
| 02:50 ET | 416 | 5.215 |
| 02:52 ET | 1079 | 5.22 |
| 02:54 ET | 100 | 5.22 |
| 02:57 ET | 100 | 5.22 |
| 02:59 ET | 100 | 5.22 |
| 03:01 ET | 467 | 5.21 |
| 03:03 ET | 5820 | 5.225 |
| 03:06 ET | 1416 | 5.225 |
| 03:08 ET | 500 | 5.23 |
| 03:12 ET | 100 | 5.23 |
| 03:14 ET | 1265 | 5.2323 |
| 03:17 ET | 100 | 5.22 |
| 03:21 ET | 500 | 5.23 |
| 03:30 ET | 242 | 5.24 |
| 03:32 ET | 200 | 5.24 |
| 03:33 ET | 400 | 5.23 |
| 03:37 ET | 717 | 5.23 |
| 03:39 ET | 1200 | 5.22 |
| 03:42 ET | 3423 | 5.21 |
| 03:44 ET | 5599 | 5.22 |
| 03:46 ET | 100 | 5.22 |
| 03:48 ET | 1177 | 5.205 |
| 03:50 ET | 600 | 5.2 |
| 03:51 ET | 7794 | 5.2171 |
| 03:53 ET | 799 | 5.21 |
| 03:55 ET | 100 | 5.22 |
| 03:57 ET | 4931 | 5.2 |
| 04:00 ET | 52033 | 5.18 |
Oct 31, 2024
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 318.5M | -8.1x | --- |
Jasper Therapeutics Inc | 321.3M | -4.3x | --- |
Compass Pathways PLC | 324.8M | -2.0x | --- |
Nautilus Biotechnology Inc | 327.3M | -4.6x | --- |
Biomea Fusion Inc | 327.3M | -2.2x | --- |
Rezolute Inc | 307.6M | -4.1x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $318.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
